These results indicate a total impairment in IL2Rγc survival signaling in CD4+ T cells by tumor-secreted PGE2. All these factors were restored back to their original levels up on prior treatment of tumor cells with theaflavins (Fig. 5A) thereby protecting CD4+ cells from tumor-induced apoptosis. This evidence concerns the gene CD4 and neoplasm.